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a b s t r a c t
Introduction: Accelerated atherosclerosis has been shown in some autoimmune diseases, 
mainly in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Although high preva-
lence of corticosteroids use may be a confounding factor due to their detrimental effects 
on several risk factors, systemic inflammation per se is supposed to play an important role 
in atherogenesis in these patients. 
Methods: We have evaluated sub-clinical atherosclerosis and plasma levels of circulating 
electronegative LDL, which represents the fraction of LDL that is minimally modified, in 
patients with ankylosing spondylitis (AS). Fourteen patients who fulfilled the modified New 
York criteria for AS were compared with 13 paired controls. Carotid intimal-media thick-
ness (IMT) was assessed by ultrasonography bilaterally in common carotid artery, internal 
carotid artery and in the bifurcation. Groups were homogeneous regarding cardiovascular 
risk factors. Only a single patient in AS group was in use of corticosteroid. 
Results: The presence of active inflammation was demonstrated by elevated BASDAI and 
higher CRP levels and in patients versus controls (12.36 vs. 3.45 mg/dl, P = 0.002). No dif-
ference was found in carotid IMT between both groups, in any site of artery. Averaged IMT 
(6 measurements, at 3 pre-specified sites bilaterally) was 0.72 ± 0.28 in AS group and 0.70 
± 0.45 mm in controls (P = 0.91). Minimally modified LDL did not differ significantly either 
between patients and controls (14.03 ± 17.40 vs. 13.21 ± 10.21; P = 0.88).
Conclusions: Patients with AS did not show increased carotid IMT in comparison to con-
trols. In the same way, circulating plasma levels of LDL (-), did not differ significantly in 
both groups.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Avaliação da aterosclerose subclínica e de níveis plasmáticos de LDL 
minimamente modificada em pacientes com espondilite anquilosante e 






Espessura da íntima-média da 
carótida
r e s u m o
Introdução: A aterosclerose acelerada foi demonstrada em algumas doenças autoimunes, 
principalmente lúpus eritematoso sistêmico e artrite reumatóide. Embora a alta prevalên-
cia do uso de corticosteróides possa ser um fator complicador, por causa de seus efeitos 
prejudiciais em diversos fatores de risco, acredita-se que, nesses pacientes, a inflamação 
sistêmica per se desempenhe papel importante na aterogênese. 
Métodos: Avaliamos a aterosclerose subclínica e os níveis plasmáticos de LDL eletronegativa 
circulante em pacientes com espondilite anquilosante (EA). Catorze pacientes que aten-
diam aos critérios de Nova York modificados para EA foram comparados com 13 controles 
equiparados. Avaliamos a espessura da íntima-média (EIM) na carótida por ultrassonogra-
fia bilateral da artéria carótida comum, artéria carótida interna e na bifurcação. Os grupos 
foram homogêneos, no que tange a fatores de risco cardiovasculares. Apenas um paciente 
no grupo de EA estava sendo medicado com corticosteróide. 
Resultados: A presença de inflamação ativa foi demonstrada por BASDAI elevado e níveis 
mais elevados de PCR em pacientes versus controles (12,36 vs. 3,45 mg/dl, P=0,002). Não ob-
servamos diferença na EIM da carótida entre os dois grupos, em qualquer local da artéria. A 
média de EIM (6 mensurações em 3 locais pré-especificados, bilateralmente) foi 0,72 ± 0,28 
no grupo de EA e 0,70 ± 0,45 mm nos controles (P=0,91). Também não observamos diferença 
significativa na LDL minimamente modificada entre pacientes e controles (14,03 ± 17,40 vs. 
13,21 ± 10,21; P=0,88).
Conclusões: Pacientes com EA não demonstraram aumento na EIM da carótida, em com-
paração com controles. Do mesmo modo, os níveis plasmáticos circulantes de LDL(-) não 
diferiram significativamente nos dois grupos.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Atherosclerosis is a progressive disease of the large and medi-
um size arteries involving inflammation, lipid accumulation, 
cell death, and thrombosis in vessel wall.1 The “response to 
injury hypothesis” postulates that long-term endothelial cell 
injury alters endothelial permeability to low density lipopro-
teins (LDL) and induces leukocyte adhesion and migration to 
sub-endothelial space.2 Regardless of the risk factor inducing 
endothelial disfunction, the following inflammation process 
will lead to plaque formation. The uptake of oxidized LDL (Ox-
LDL), but not native LDL, by macrophages in vessel wall will 
lead to the formation of foam cells that are not only a reser-
voir of modified lipids, but also a source of proinflammatory 
mediators contributing to plaque progression.3
Therefore, proinflammatory OxLDL may be a unifying link 
between lipid accumulation and inflammation.4 Although 
most of the oxidation of LDL occurs in the vessel wall, lipopro-
teins can be minimally modified in plasma becoming more 
prone to oxidation on a subsequent entry into the intima.5 
A more electronegative subfraction of LDL, called LDL(-) has 
been subfractionated by high resolution ion exchange chro-
matography (IE-HPLC) and seems to represent circulating 
minimally modified LDL in plasma.6
The recognition that inflammation is the main feature of 
atherosclerotic disease has led to a series of studies report-
ing high prevalence of atherosclerosis in chronic inflamma-
tory diseases, such as rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE).7,8 There is a twofold increased 
risk for myocardial infarction and stroke in patients with RA, 
with risk increasing to nearly threefold in those who have the 
disease for 10 years or more.9 These increased morbidity and 
mortality due to atherosclerosis seem to depend not only on 
traditional RF, that may be negatively affected by corticoste-
roid use. Inflammatory mechanisms seem to be associated 
with worse cardiovascular outcomes in this patients.10-12 Al-
though some controversial results have been published, an-
other plausible mechanism for accelerated atherosclerosis in 
these patients may be an increased level of OxLDL.13
Ankylosing spondylitis (AS) is a chronic rheumatic disease 
that compromises mainly the spine and sacroiliac joints. De-
spite its inflammatory origin like AR and SLE, it is not totally 
clear if atherosclerosis accounts for higher mortality in these 
patients.14,15 As steroids are not commonly part of clinical 
treatment of these patients, AS may be a better model to eval-
uate the role of inflammation in atherosclerosis. In this study 
we evaluated subclinical atherosclerosis (carotid intimal-me-
dia thickness – IMT) and plasma levels of minimally modified 
LDL (LDL(-)) in patients with AS in comparison to controls.
Methods
Study population
In this cross-sectional study we enrolled 14 patients who ful-
filled the modified New York16 criteria for AS and 13 controls. 
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Written informed consent was obtained from all subjects and 
the research protocol was approved by the Ethical Committee 
of the Catholic University of Paraná. 
The essentials of diagnosis of AS were inflammatory back 
pain (IBP) in young adults, generally worst in the morning; 
progressive limitation of back motion and chest expansion; 
peripheral arthritis; anterior uveitis; diagnostic radiographic 
changes in sacroiliac joints and elevated erythrocyte sedi-
mentation rate (ESR) or C-reactive protein (CRP). Patients 
were recruited in the ADORE Association, a Brazilian as-
sociation of rheumatic patients. All enrolled patients had 
axial disease without peripheral arthritis or extra-articular 
manifestations. Controls were enrolled in a 1:1 ratio matched 
for age, sex and CVD risk factors status. Subjects were also 
questioned about lifestyle and clinical information. Age, gen-
der, BASDAI and BMI were recorded. Blood samples were col-
lected for the biochemical measurements of complete lipid 
profile, fasting blood glucose, hematology evaluation, eryth-
rocyte sedimentation rate, CRP and minimally modified LDL. 
Samples were collected in the morning, after a fasting period 
of 10-12h; serum and plasma were separated and frozen at 
-22°C. Cholesterol and triglyceride levels were determined by 
fully enzymatic techniques. LDL cholesterol was calculated as 
described by Friedwald formula. High sensitivity CRP was as-
sessed by turbidimetry methodology.
Minimally modified LDL (LDL(-))
The plasma LDL fraction is comprised of a heterogeneous 
population of particles that varies with respect to charge,17 
density, size, antioxidant content, presence of apoproteins 
other than apoB and degree of oxidative modification.18 Con-
centrations of LDL(-) in blood plasma were determined by 
ELISA using two anti-minimally human LDL monoclonal anti-
bodies (MAb 1A3 and MAb 2C7).
Microplates (EIA/RIA, Costar, Cambridge, Mass., USA) were 
coated with 50μl MAb 1A3 (1μg/well) in carbonate-bicarbon-
ate buffer (pH 9.4, 0.1M) and incubated overnight at 4°C. Then, 
each microplate was washed three times with phosphate-
buffered saline (PBS; Tris-HCl 50mM and NaCl 150mM, pH 7.4) 
containing tween 20 (0.5%) and blocked with 5% nonfat dry 
milk for 2 hours at 37°C. The microplates were washed again 
and incubated with 50μL plasma for 2 hours at 37°C. The 
plates were washed and incubated with anti-LDL MAb 2C7 bi-
otinylated for 2 hours at 37°C. After washing, the microplates 
were incubated with streptavidin-HRP (horseradish peroxi-
dase) conjugate (Rockland Immunochemicals for Research, 
Gilbertville, Pa., USA) for 1 hour at 37°C. Then, the OPD sub-
strate solution was added to each well. The absorbance was 
determined immediately using a microplate reader (Spectral-
Count Microplate Photometer, Packard Instruments Company, 
Downers Grove, IL, USA). The calibration curve was made with 
LDL obtained from human plasma. All samples and standards 
were run in triplicate. The intra-assay and interassay varia-
tions for this ELISA test were 8% and 15%, respectively.
Carotid intima-media thickness assessment
Carotid IMT is associated with the risk of coronary artery 
disease, stroke and myocardial infarction and predicts the 
progression of CVD19. Measurement of IMT was taken at the 
common distal carotid (1-2cm proximal to carotid bifurca-
tion), bilaterally in the bifurcation and in the internal carotid, 
as well as at the origin of the right subclavian artery. 
During the analysis, the greatest right and left carotid 
IMT values were considered, as well as the value measured 
at the origin of the right subclavian artery. The right subcla-
vian artery was easily evaluated since it is more superficial 
than the contra-lateral subclavian artery; however, this does 
not denote advantages or technical limitations relative to the 
carotid arteries. The measurement of the intima-media com-
plex was performed with Siemens Sonoline Elegra® vascular 
ultrasonography equipment. A 7.5 mHz linear transducer was 
used, with a frequency range of 7-9 mHz, longitudinal section 
and B-mode images. Thickness measurement was performed 
at the anterior or posterior artery wall, as the distance be-
tween two echogenic lines corresponding to the lumen-inti-
ma and media-adventitia interfaces of the artery wall.
Statistical analysis
All analyses were performed with GraphPad Prism (Version 
3.02, GraphPad Software Incorporated). Continuous variables 
are presented as means ± standard deviation, and categori-
cal variables as number and percentages. The two groups 
were compared using the Student t-test. Chi-square statistics 
were used to assess differences between categorical variables. 
Pearson’s correlation analysis was used to test univariate re-
lations. Prediction of independent variables was obtained by 
stepwise, forward, multiple regression model including po-
tential confounders. A P value of < 0.05 was considered sig-
nificant.
Results
Initially 33 subjects were screened for the study. Twenty seven 
of those were found eligible and willing to participate. The 
baseline characteristics of patients and controls are present-
ed in Table 1. 
Subjects were predominantly male, and mean age of the 
patients was 45.14 years ± 8.99 vs 46.75 years ± 8.40 of the 
controls (P = 0.642). Systolic and diastolic blood pressure was 
similar in both groups. Body mass index (kg/m2), was 25.60 
± 5.02 for AS group and 28.34 ± 4.09 for controls (P = 0.139). 
The abdominal circumference in patients and controls was, 
respectively, 94.0 ± 14.3 cm vs. 93.8 ± 14.3 (P = 0.976). As ex-
pected, BASDAI was higher in AS patients than in controls (5.6 
± 1.2 vs 1.3 ± 0.7; P = 0.047). Prevalences of hypertension and 
diabetes were similar in both groups. Mean time of diagnosis 
was 12 years for the patients with AS. Only a single patient 
was in use of corticosteroids. No patient was using anti-TNFs.
Biochemical parameters are presented in Table 2. Lipid 
profile was similar in both groups, with no difference regard-
ing total cholesterol, HDL cholesterol, triglycerides and LDL 
cholesterol. Most inflammatory markers were elevated in pa-
tients with AS. Patients had higher levels of CRP (12.36 ± 7.99 
vs. 3.45 ± 4.81; P = 0.002) and total leukocyte count (9550 ± 2256 
vs. 6915 ± 1721; P = 0.003). ESR did not differ significantly in 
both groups. Platelet count was also higher in patients with 
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AS (334,000 ± 106,000 vs. 252,000 ± 66,000; P = 0.028), as have 
been previously demonstrated in other rheumatic diseases.20 
Although subjects were matched for diabetes, glucose level 
was higher in control than in AS patients (95.43 ± 10.53 vs. 
109.1 ± 13.33; P = 0.009). LDL(-) did not differ significantly be-
tween patients with AS and controls (14.03 ± 17.40 vs. 13.21 ± 
10.21; P = 0.88).
Data regarding carotid IMT are summarized in Table 3. 
Regardless of the location (internal, bifurcation or common 
carotid) and side (left or right) of the artery where IMT was as-
sessed, no difference was found between the two groups. As 
previously described, right subclavian was also evaluated and 
no difference was found either.
Discussion
Atherosclerosis is an inflammatory condition and inflamma-
tion experienced in chronic immune diseases may contrib-
ute to accelerate atherosclerosis in this situations.21 In this 
study, despite of active inflammation as demonstrated by 
high CRP levels and BASDAI, patients with AS did not show 
higher prevalence of sub-clinical atherosclerosis, as demon-
strated by carotid IMT. In the same way, circulating plasma 
levels of LDL(-), which represents the fraction of LDL that 
is minimally modified, did not differ significantly in both 
groups.
Our study is in accordance with a previous study that also 
demonstrated lack of correlation between AS and increased 
IMT.22 In the study by Sari et al., young age of patients (mean 
age, 37 years old) could have explained, at least in part, the 
lack of correlation if inflammation was really assumed as 
an important factor for atherosclerosis development. In the 
same study, a compromised endothelial function, as dem-
onstrated by impaired flow mediated dilation of brachial ar-
tery, was also shown. This could be interpreted as evidence 
that maybe patients were evaluated in a very initial phase of 
atherosclerosis development, since endothelial dysfunction 
precedes the morphological changes in arterial wall.23
Whether age (mean, 45 years old) was a limiting factor 
in our study is not known. Considering patients with other 
rheumatologic conditions, not only IMT is already increased 
in the fourth decade,24 but also the length of disease (the 
mean time of diagnosis in our population was 12 years) is a 
determinant of thickening.25
In a publication where IMT was also assessed in patients 
with AS, only a trend towards increased thickness was 
seen.26 Similarly to our study, patients in control group had a 
slight worse metabolic profile than patients in AS, specially 
glucose levels.26 An interesting finding in this study was that 
arterial stiffness, another marker of subclinical atheroscle-
rosis, was not modified by TNF-α inhibitors, suggesting that 
modulation of inflammatory response has no effect on ar-
terial wall injury.26 None of our patients were being treated 
with TNF-α inhibitors.
This was the first study to evaluate plasma levels of LDL(-
) in patients with AS. Although elevated levels of oxidized 
LDL have been previously reported in patients with other 
autoimmune diseases,27 little has been published regard-
ing minimally modified LDL. These moieties are more prone 
to be oxidized when into the sub-endothelial space, where 
most of oxidation process occurs. 
Although not as pro-atherogenic as oxidized LDL, mini-
mally modified forms induce monocyte adhesion to endo-
thelial cells and MCP-1 production, critical steps in early 
atherogenesis.28,29 The source of these minimally modified 
forms remains unclear; however, there are possible sourc-
es:30 oxidation of LDL in the arterial wall followed by egress 
Table 1 – Clinical characteristics of the ankylosing 
spondylitis and control groups.






Age (years) 45.14 ± 8.99 46.75 ± 8.40 0.642
Male(%) 78.57 76.92
Body mass index (kg.m-2) 25.60 ± 5.02 28.34 ± 4.09 0.139
Abdominal 
circumference (cm)
94 ± 14.34 93.83 ± 14.31 0.976
DM (%) 7.14 7.70
Hyperlipidemia (%) 21.43 30.77
Diastolic blood pressure 
(mmHg)
78.93 ± 12.12 76.67 ± 6.51 0.552
Hypertension (%) 21.43 30,77
BASDAI 5.6 ± 1.2  1.3 ± 0.7 0.0712
AS, ankylosing spondylitis; DM, diabetes mellitus; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index.
Table 2 – Biochemical parameters of the ankylosing 









Cholesterol (mg/dL) 185.40 ± 34.88 221.60 ± 59.46 0.080
HDL (mg/dL) 46.79 ± 10.64 44.25 ± 11.11 0.559
Triglycerides (mg/dL) 131.20 ± 66.53 196.40 ± 105.20 0.080
LDL (mg/dL) 112.10 ± 29.10 140.70 ± 47.80 0.099
LDL(-) (U/L) 14.03 ± 17.40 13.21 ± 10.21 0.880
Glucose (mg/dL) 95.43 ± 10.53 109.10 ± 13.33 0.009
Leukocytes 9550 ± 2256 6915 ± 1721 0.003
Platelets (x103) 334 ± 106 252 ± 66 0.028
ESR (mm) 21.64 ± 15.01 15.64 ± 12.42 0.285
CRP (mg/L) 12.36 ± 7.99 3.45 ± 4.81 0.002
AS, ankylosing spondylitis; DM, diabetes mellitus; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index.
Table 3 – Doppler ultrasonography assessment of 
intima-media thickness (IMT) of left (L) and right (R) 









Left common  carotid (mm) 0.58 ± 0.13 0.69 ± 0.53 0.461
Left bifurcation (mm) 0.86 ± 0.42 0.85 ± 0.35 0.982
Left internal  carotid (mm) 0.74 ± 0.54 0.67 ± 0.15 0.623
Right common carotid (mm) 0.55 ± 0.16 0.55 ± 0.12 0.944
Right bifurcation (mm) 0.82 ± 0.37 0.80 ± 0.42 0.889
Right internal carotid (mm) 0.79 ± 0.53 0.70 ± 0.45 0.652
Right subclavian (mm) 1.16 ± 0.62 0.95 ± 0.30 0.287
AS, ankylosing spondylitis.
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into the circulation, ingestion of oxidized fats and/or genera-
tion from postprandial lipoprotein remnants or direct oxida-
tion in blood plasma. Regardless of the source, our findings 
do not support any role of inflammation in this initial modi-
fication of LDL particle. Not only plasma levels were similar 
in AS and control group, but also no correlation was found 
between minimally modified LDL and CRP levels (data not 
shown). Whether the same concept can be applied to oxi-
dized LDL levels in patients with AS remains to be exploited. 
In patients with SLE and RA, not only oxidized LDL, but also 
their autoantibodies, are associated to atherosclerosis.31,32
It is not clear why most of the data from patients with 
AS are in the opposite direction of studies with SLE and RA 
regarding atherosclerosis. It’s worth mentioning that corti-
costeroids treatment is always a confounding factor in these 
studies. While commonly prescribed in patients with RA and 
SLE, this is not a first line treatment in AS. In our study, a 
single patient was in use of prednisone. Mainly when used 
in high doses, corticosteroids have an important detrimen-
tal effect on several cardiovascular risk factors. These effects 
can be in part responsible for the accelerated atherosclerosis 
seen in patients with SLE and RA.33,34 Further studies includ-
ing higher number of patients with AS taking steroids could 
clarify this issue.
This study has potential limitations. First, a small num-
ber of patients were included, and results might be seen as 
preliminary. The aim of this study was mainly to evaluate 
differences in minimally modified LDL plasma levels be-
tween patients and controls. As this biochemical parameter 
is only used for research purposes, with no “normal” values 
even in healthy individuals, a sample calculation was not 
performed by the absence of reference values or even of pre-
vious studies in patients with AS. 
Another limitation was the fact that patients with more 
physical impairment, although invited during the screen-
ing phase, did not participate. Refusal was always justified 
by difficulties in transportation. This is a frequent bias, re-
ported also in studies with RA and SLE. Once patients with 
worst clinical conditions were not included, we may have 
lost those with more complications, including atherosclero-
sis due to their inflammatory condition.
In conclusion, despite active inflammation and higher 
disease activity, there were no differences regarding plasma 
levels of minimally modified LDL and carotid IMT assessed 
by ultrasonography between patients with AS and controls. 
These findings are in accordance with previous studies in 
AS, but further and larger studies are necessary to explore 
the role of inflammation per se as an accelerating factor of 
atherosclerosis in patients with spondyloarthritis. 
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